Large-scale testing (Phase 3)Study completedNCT03746522
What this trial is testing
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Who this might be right for
Bardet Biedl Syndrome (BBS)Alström Syndrome (AS)
Rhythm Pharmaceuticals, Inc. 52